Lung cancer has the highest rate of cancer mortality among both men and women, constituting almost 25% of all cancer-related deaths. For the best chance of long-term survival, early detection of lung cancer is of essential importance.

Liquid biopsies are minimally invasive approaches that can provide a view of the molecular landscape of the tumor microenvironment in bodily fluids (blood, urine, saliva, etc.).

In a clinical study evaluated on 40 patients, the EV-GLYPH assay successfully differentiates patients with early-stage malignant lung nodules from benign lung nodules.

These results reveal the potential to profile sEV glycans for noninvasive diagnostics and prognostics, opening up promising avenues for clinical applications and understanding the role of sEV glycosylation in lung cancer.